Catheter-Based Renal Denervation: 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients With Resistant Hypertension

• Published in: Hypertension (Dallas, Tex. 1979) Tex. 1979), 2023-04, Vol.80 (4), p.811-819
• Main Authors: Sesa-Ashton, Gianni, Nolde, Janis M., Muente, Ida, Carnagarin, Revathy, Lee, Rebecca, Macefield, Vaughan G., Dawood, Tye, Sata, Yusuke, Lambert, Elisabeth A., Lambert, Gavin W., Walton, Antony, Kiuchi, Marcio G., Esler, Murray D., Schlaich, Markus P.
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Antihypertensive Agents - therapeutic use; Blood Pressure - physiology; Blood Pressure Monitoring, Ambulatory; Catheters; Denervation - methods; Female; Follow-Up Studies; Humans; Hypertension - diagnosis; Hypertension - drug therapy; Hypertension - surgery; Hypotension; Kidney - physiology; Male; Sympathectomy - adverse effects; Sympathectomy - methods; Treatment Outcome
• ISSN: 0194-911X; 1524-4563
• DOI: 10.1161/HYPERTENSIONAHA.122.20853

Recent sham-controlled randomized clinical trials have confirmed the safety and efficacy of catheter-based renal denervation (RDN). Long-term safety and efficacy data beyond 3 years are scarce. Here, we report on outcomes after RDN in a cohort of patients with resistant hypertension with an average of ≈9-year follow-up (FU). We recruited patients with resistant hypertension who were previously enrolled in various RDN trials applying radiofrequency energy for blood pressure (BP) lowering. All participants had baseline assessments before RDN and repeat assessment at long-term FU including medical history, automated office and ambulatory BP measurement, and routine blood and urine tests. We analyzed changes between baseline and long-term FU. A total of 66 participants (mean±SD, 70.0±10.3 years; 76.3% men) completed long-term FU investigations with a mean of 8.8±1.2 years post-procedure. Compared with baseline, ambulatory systolic BP was reduced by -12.1±21.6 (from 145.2 to 133.1) mm Hg (